Oncotelic Therapeutics Analysis
Oncotelic Therapeutics is undervalued with Real Value of 0.0 and Hype Value of 0.0. The main objective of Oncotelic Therapeutics otc analysis is to determine its intrinsic value, which is an estimate of what Oncotelic Therapeutics is worth, separate from its market price. There are two main types of Oncotelic Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Oncotelic Therapeutics otc stock is traded in the USA on OTCQB Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Oncotelic Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
Oncotelic |
Oncotelic OTC Stock Analysis Notes
About 56.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.89. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Oncotelic Therapeutics had not issued any dividends in recent years. The entity had 1:12 split on the 28th of December 2012. Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes and CA4P for the treatment of advanced metastatic melanoma. Oncotelic Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 16 people.The quote for Oncotelic Therapeutics is listed on Over The Counter exchange (i.e., OTC), and the entity is not required to meet listing requirements such as those found on the Nasdaq, NYSE, or AMEX exchanges. To find out more about Oncotelic Therapeutics contact Vuong Trieu at 650 635 7000 or learn more at https://www.oncotelic.com.Oncotelic Therapeutics Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more otcs at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Oncotelic Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Oncotelic Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Oncotelic Therapeutics is not yet fully synchronised with the market data | |
| Oncotelic Therapeutics has some characteristics of a very speculative penny stock | |
| Oncotelic Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Oncotelic Therapeutics currently holds 9.8 M in liabilities with Debt to Equity (D/E) ratio of 0.4, which is about average as compared to similar companies. Oncotelic Therapeutics has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Oncotelic Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Oncotelic Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Oncotelic Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Oncotelic to invest in growth at high rates of return. When we think about Oncotelic Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (9.39 M) with profit before overhead, payroll, taxes, and interest of 1.74 M. | |
| Oncotelic Therapeutics currently holds about 399.77 K in cash with (4.43 M) of positive cash flow from operations. | |
| Roughly 56.0% of Oncotelic Therapeutics outstanding shares are owned by corporate insiders |
Oncotelic Therapeutics Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Oncotelic Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 12th of April 2024 Upcoming Quarterly Report | View | |
| 27th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 12th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Oncotelic Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 23.9 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Oncotelic Therapeutics's market, we take the total number of its shares issued and multiply it by Oncotelic Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Oncotelic Therapeutics Outstanding Bonds
Oncotelic Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Oncotelic Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Oncotelic bonds can be classified according to their maturity, which is the date when Oncotelic Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our otc stock analysis tools, you can find out how much better you can do when adding Oncotelic Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Share Portfolio Now
Share PortfolioTrack or share privately all of your investments from the convenience of any device |
| All Next | Launch Module |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Other Consideration for investing in Oncotelic OTC Stock
If you are still planning to invest in Oncotelic Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oncotelic Therapeutics' history and understand the potential risks before investing.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |